CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
Neoadjuvant/adjuvant IDE196 (darovasertib) in patients with primary uveal melanoma...
Phase 2
Durham, North Carolina, United States and 24 other locations
cell death protein-1 (PD-1) inhibitor, in patients with metastatic melanomas or advanced solid tumors. Our hypothesis is that restoration of...
Phase 1, Phase 2
Durham, North Carolina, United States and 20 other locations
efficacy of belzupacap sarotalocan (bel-sar) compared to sham control in patients with primary indeterminate lesions (IL) or small choroidal melanoma...
Phase 3
Durham, North Carolina, United States and 45 other locations
Patients in the study will be treated with Melphalan/HDS and will receive up to 6 total treatments.This study will evaluate the safety and effects of...
Phase 3
Durham, North Carolina, United States and 4 other locations
To evaluate the overall survival of HLA-A\*0201 positive adult patients with previously untreated advanced UM receiving IMCgp100 compared to Investig...
Phase 2
Durham, North Carolina, United States and 55 other locations
antigen (HLA)-A\*02:01 negative participants with metastatic uveal melanoma (MUM) who will be randomized to receive either IDE196 + crizotin...
Phase 2, Phase 3
Durham, North Carolina, United States and 65 other locations
of up to 2 dose selection cohorts to evaluate the safety and tolerability of dapansutrile + pembrolizumab in patients with PD-1 resistant melanoma...
Phase 1, Phase 2
Durham, North Carolina, United States
to assess nivolumab plus relatlimab fixed-dose combination (FDC) versus nivolumab alone in participants with completely resected stage III-IV melanoma...
Phase 3
Durham, North Carolina, United States and 171 other locations
be those with pathological diagnosis of unresectable or metastatic melanoma who are progressing or have progressed on either pembrolizumab o...
Phase 2
Durham, North Carolina, United States and 32 other locations
manner the recurrence-free survival (RFS) of Stage IIIB/C melanoma patients with respect to the standard of care (surgery and adjuvant thera...
Phase 3
Durham, North Carolina, United States and 33 other locations
Clinical trials
Research sites
Resources
Legal